We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




High Thyroid Hormone Levels Associated with Arterial Disease

By LabMedica International staff writers
Posted on 15 Nov 2017
Atherosclerosis is the process of progressive thickening and hardening of the walls of arteries from fat deposits on their inner lining. More...
Atherosclerosis progresses insidiously from a subclinical condition to the clinical onset of vascular events to death.

High and high-normal levels of a thyroid hormone called free thyroxine 4 (FT4), are associated with artery disease and death in elderly and middle-aged people. FT4 is a hormone produced by the thyroid gland that helps control the rate at which the body uses energy.

Medical scientists at the Erasmus Medical Center (Rotterdam, The Netherlands) carried out a prospective population-based cohort study that investigated the determinants, occurrence and progression of chronic diseases in the middle-aged and elderly. Baseline measurements for the study were performed during the third visit of the first cohort of 4,797 and the first visit of the second of group of 3,011 and third cohort of 3,932 in the Rotterdam Study.

Thyroid function was assessed at baseline in three study cohorts using the same method and assay. Measurements of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and thyroid peroxidase antibodies (TPOAb) were performed in baseline serum samples stored at -80 °C using the electrochemiluminescence immunoassay ECLIA. The reference ranges of serum TSH (0.40–4.0 mIU/L) and serum FT4 (0.86–1.94 ng/dL; equivalent to 11–25 pmol/L) were determined.

The team found that after a median follow-up of 8.8 years, there were 612 atherosclerosis-related cardiovascular deaths and 934 first-time atherosclerosis-related cardiovascular events. Increasing FT4 levels were associated with twice the odds of having high levels of coronary artery calcification scores, which may be an indicator of subclinical atherosclerosis; 87% greater risk of suffering an atherosclerosis-related cardiovascular event; and double the risk of atherosclerosis-related cardiovascular death. The authors conclude that FT4 levels in middle-aged and elderly subjects were positively associated with atherosclerosis throughout the whole disease spectrum, independently of cardiovascular risk factors.

Arjola Bano, MD, MSc, DSc, the lead study author, said, “We expected that thyroid function would influence the risk of developing atherosclerosis by affecting cardiovascular risk factors such as blood pressure. However, our results remained very similar after accounting for several cardiovascular risk factors. This suggests that mechanisms other than traditional cardiovascular risk factors may play a role. Our findings suggest that thyroid hormone FT4 measurement can help identify individuals at increased risk of atherosclerosis.” The study was published on October 31, 2017, in the journal Circulation Research.

Related Links:
Erasmus Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.